Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors;Prevalencia de enfermedad cardiovascular en la uremia y relevancia de los factores de riesgo cardiovascular

Nefrologia

Volumn 30, Issue 3, 2010, Pages 342-348

  Collado, S ^a   Coll, E ^b   Deulofeu, R ^c   Guerrero, L ^c   Pons, M ^d   Cruzado, J M ^e   de la Torre, B ^f   Vera, M ^c   Azqueta, M ^c   Nicolau, C ^c   Cases, A ^c  

^a HOSPITAL DEL MAR   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CETIRSA   (Spain)

^e Instituto de Hemodiálisis   (Spain)

^f CD Bonanova   (Spain)

Author keywords

Cardiovascular disease; Cardiovascular risk factors; End stage renal disease

Indexed keywords

ARGININE; BIOLOGICAL MARKER; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; PLASMA PROTEIN;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; HEART STROKE VOLUME; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PREVALENCE; RISK FACTOR; SMOKING; UREMIA;

AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK FACTORS; SMOKING; STROKE VOLUME; UREMIA;

EID: 77954627502     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Apr.10410     Document Type: Article

References (24)

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn, Where do we go from here? Am J Kidney Dis 1998;32:853-906.
2. Rostand SG, Brunzell JD, Cannon RD, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-62.
3. Parfrey PS, Harnett JD. Long-term cardiac morbidity and mortality during dialysis therapy. Adv Nephrol 1994;23:311-31.
4. USRDS US Renal Data System 1999. Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD. www.usrds.org/adr_1999.htm
5. Sarnak MJ, Levey AS. Epidemiology of cardiac disease in dialysis patients. Semin Dial 1999;12:69-76.
6. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000;15:454-7.
7. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007;50(3):217-24.
8. Shah DS, Polkinghorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology 2008;13:667-71.
9. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48.
10. Zannad F, Kessler M, Lehert P, Grünfeld J P, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006;70:1318-24.
11. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
12. Joki N, Hase M, Fukazawa M, Nakamura R, Ishikawa H, Tanaka Y, Inishi et al. Progression of coronary atherosclerosis is accelerated in hemodialyzed patients than chronic renal insufficiency patients. Nephrol Dial Transplant 1999;14:171A.
13. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dialysis 2002;15:329-37.
14. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005;45:39-47.
15. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002;17(Supl 11):50-4.
16. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassesing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8:475-86.
17. London GM, Guerin A P, Marchais SJ, Pannier B, Safar M, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
18. Blacher J, Safar ME, Pannier B, Guerin A P, Marchais SJ, London GM. Prognostic significance of arterial stiffness measurements in end-stage renal disease patients. Curr Opin Nephrol Hypertens 2002;11:629-34.
19. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006;92:1402-8.
20. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-62.
21. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
22. Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 2009;29:257-63.
23. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al.; APPROACH Investigators. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-92.
24. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407.